Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner E H
Br J Dermatol. 1986 Oct;115(4):393-401. doi: 10.1111/j.1365-2133.1986.tb06233.x.
Scl 70 antibodies were tested for in 107 patients with systemic sclerosis: 68 with acrosclerosis and 39 with diffuse scleroderma. Anticentromere antibodies (ACA) and other antinuclear antibodies (ANA) were tested for by indirect immunofluorescence on HEp-2 cells. Positive results for Scl 70 antibodies were obtained in 77% of cases of diffuse scleroderma and 44% of acrosclerosis. ACA and Scl 70 antibodies were found to be mutually exclusive. If acrosclerosis cases positive for anticentromere antibodies are excluded, the percentage of acrosclerosis cases positive for Scl 70 was 63%. ACA were found to be a marker of a benign, abortive subset of acrosclerosis with almost no cutaneous involvement (CREST), whereas Scl 70 did not discriminate between acrosclerosis and diffuse scleroderma. On HEp-2 cells Scl 70 positive sera gave a characteristic, fine speckled, almost homogeneous nuclear staining pattern.
对107例系统性硬化症患者检测了Scl 70抗体：68例为肢端硬化症，39例为弥漫性硬皮病。通过间接免疫荧光法在人喉上皮癌细胞（HEp-2细胞）上检测抗着丝点抗体（ACA）和其他抗核抗体（ANA）。弥漫性硬皮病患者中77%的病例Scl 70抗体检测呈阳性，肢端硬化症患者中44%呈阳性。发现ACA和Scl 70抗体相互排斥。如果排除抗着丝点抗体阳性的肢端硬化症病例，Scl 70阳性的肢端硬化症病例百分比为63%。发现ACA是肢端硬化症中几乎无皮肤受累的良性、顿挫型亚组（CREST综合征）的标志物，而Scl 70不能区分肢端硬化症和弥漫性硬皮病。在HEp-2细胞上，Scl 70阳性血清呈现特征性的、细小斑点状、几乎均匀的核染色模式。
